$GNHAF News

Last published 4y ago

4y agoGNHAFVifor Pharma reports sustained growth in 2021Business WireNet sales up 4.0% and EBITDA up 6.6% at constant exchange rates (CER) a result of profitable growth in net sales combined with diligent cost containment Iron franchise – Ferinject® / Injectafer® sales up 20.1% at CER reflecting strong recover
4y agoGNHAF OPKRAYALDEE® Launched in Germany by OPKO Health's Licensee, VFMCRPGlobeNewswireMIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE® (extended release calcifediol) in Germany, the first launch of R
4y agoGNHAFVifor Pharma appoints two new members to the Executive CommitteeBusiness WireExecutive appointments to strengthen financial and legal leadership during the transformation of the company Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced the appointment of acting Chief Fina
4y agoGNHAFVFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitisBusiness WireFirst orally administered therapy for the treatment of the two main types of ANCA-associated vasculitis approved in Europe First launches expected in H1 2022 Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announc
4y agoCSLLY GNHAF GNHAYCSL BEHRING AG PUBLISHES OFFER PROSPECTUS ON PUBLIC TENDER OFFER FOR ALL PUBLICLY HELD SHARES OF VIFOR PHARMA LTD.PR NewswireMELBOURNE, Australia and ST. GALLEN, Switzerland, Jan. 18, 2022 /PRNewswire/ -- CSL Behring AG, Berne, Switzerland, a wholly-owned subsidiary of global biotechnology leader CSL Limited ((ASX: CSL, OTC:CSLLY), today published the offer prospectus regardin
4y agoCSLLY GNHAFCSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd.Business WireRegulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220117005418/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR CSL Behring AG, Berne, Switzerland, a wholly-owned sub
4y agoGNHAFVifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa®Business WirePhase-IIIb trial demonstrates statistically significant outcome on the primary endpoint Largest study to date showing benefit of Veltassa® (patiromer) in high risk patient population with heart failure Results suggest that treatment with Velt
4y agoGNHAFVifor Pharma and American Regent announce settlement of Injectafer® patent litigationBusiness WireAbbreviated New Drug Application (ANDA) disputes regarding Injectafer® (ferric carboxymaltose) have now been settled Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20
4y agoGNHAFVifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharmaBusiness WireFocus on expansion in nephrology, and to maximize opportunities on the iron portfolio Vifor Pharma to divest non-core assets on finished drug product facilities to CordenPharma, reducing organizational complexity, and optimizing cost structure
4y agoCSLLY GNHAFCSL Limited Announces Tender Offer To Acquire Vifor Pharma LtdPR NewswireMELBOURNE, Australia and ST. GALLEN, Switzerland, Dec. 14, 2021 /PRNewswire/ -- CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd- Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021- Expands CSL
4y agoCSLLY GNHAFCSL Limited announces tender offer to acquire Vifor Pharma LtdBusiness WireAgreement announced on the Australian Securities Exchange and SIX Swiss Exchange on 14 December 2021 Cash offer at US$179.25 per share Offer equivalent to CHF167 per share1 Proposed ordinary dividend expected to be declared at AGM of 26 Ap
4y agoGNHAFVifor Pharma comments on media speculationBusiness WireRegulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this. Until then, Vifor does not comment on these discussions
4y agoGNHAFFirst patient enrolled in phase-IIa study of vamifeport in patients with sickle cell diseaseBusiness WireVamifeport (VIT-2763) is the first oral ferroportin inhibitor investigated for treatment of diseases with ineffective production of red blood cells and iron overload such as sickle cell disease (SCD) SCD is a rare blood disorder with currently lim
4y agoGNHAFVifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive CommitteeBusiness WireHervé Gisserot will join Vifor Pharma as Chief Commercial Officer on 17 January 2022 Responsibilities of Sales, Marketing and Market Access to be streamlined under Chief Commercial Officer role to prioritize commercial execution Regula
4y agoANGN GNHAFVifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injuryBusiness WireRegulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211209006035/en/ AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma and Angion Biomedica Corp. (NASDAQ:ANGN)
4y agoANGN GNHAFAngion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney InjuryGlobeNewswire-- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2
4y agoGNHAFVifor Pharma comments on market speculationsBusiness WireRegulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Due to current market speculations, Vifor Pharma Group states the following: Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate
4y agoGNHAFVifor Pharma announces changes to the Executive Committee as CFO retiresBusiness WireColin Bond to retire as Chief Financial Officer of Vifor Pharma Group Succession recruitment ongoing Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced that Colin Bond, Chief Financial Officer
4y agoGNHAFVifor Pharma supports Iron Deficiency Day 2021: Call to action for early iron deficiency diagnosisBusiness WireIron Deficiency Day unites a strong international coalition dedicated to raising international awareness on the serious health impact of iron deficiency and iron deficiency anemia1 Patient access to diagnosis and treatment of iron deficiency direc
4y agoGNHAFVifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrologyGlobeNewswirePress Release Vifor Pharma to acquire Sanifit to further strengthen late-stage pipeline in nephrology Vifor Pharma to acquire Sanifit, a clinical-stage cardio-renal biopharmaceutical company focused on treatments for progressive vascular calcific
4y agoGNHAFVifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AGBusiness WireSanifit Therapeutics and Inositec AG, both clinical stage biopharmaceutical companies, are developing first-in-class treatments for progressive vascular calcification and soft tissue disorders Sanifit's SNF472 is a novel, first-in-class inhibitor
5y agoGNHAFVFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitisBusiness WireCommittee for Medicinal Products for Human Use (CHMP) recommends approval of first orally administered therapy for the treatment of ANCA-associated vasculitis (GPA and MPA) in Europe European Commission decision for EU Marketing Authorization expe
5y agoANGN GNHAFVifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft functionBusiness WirePhase-III trial did not demonstrate a statistically significant difference from placebo on the primary endpoint of estimated Glomerular Filtration Rate (eGFR) at 12 months in patients at risk for delayed graft function (DGF) Safety profile of ANG-
5y agoANGN GNHAFAngion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft FunctionGlobeNewswireUNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from
5y agoGNHAFVifor Pharma announces changes to its Executive CommitteeBusiness WireExecutive committee members Lee Heeson and Gregory Oakes to leave the company for personal reasons Succession planning ongoing Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma Group today announced changes to its
5y agoGNHAFVFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in JapanBusiness WireFirst orally administered therapy for the treatment of two types of ANCA-associated vasculitis approved in Japan Partner Kissei to market TAVNEOS® in Japan, with launch expected as soon as possible following National Health Insurance (NHI) price
5y agoGNHAF TVTXVifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New ZealandBusiness WireSparsentan is a potential first-in-class treatment to address significant unmet medical need in rare kidney disorders focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) Vifor Pharma obtains exclusive commercialization rights for
5y agoGNHAF TVTXTravere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New ZealandGlobeNewswireVifor Pharma obtains exclusive commercialization rights for sparsentan in Europe, Australia and New Zealand Travere receives a $55 million upfront payment and is eligible for additional regulatory and commercial milestones, as well as tiered royalties
5y agoGNHAFVifor Pharma's Ferinject® granted new recommendations in updated 2021 ESC heart failure guidelinesBusiness Wire2021 European Society of Cardiology (ESC) guidelines for acute and chronic heart failure (HF) includes new recommendations on management of iron deficiency with Ferinject® (ferric carboxymaltose) in patients with HF Periodic screening for iron de
5y agoCARA GNHAFVifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsBusiness WireAD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in
5y agoCARA GNHAFCara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patientsGlobeNewswireFirst and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis Promotional launch of KORSUVA™ injection in the U.S. is expected in Q1 2022, with reimbursemen
5y agoGNHAFVifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1Business WireNet sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key markets Ferinject® / Injectafer® sales up 22.8% at CER ‒ strong recovery in Q2 in line with loc
5y agoGNHAFAbbas Hussain Appointed as New Chief Executive Officer of Vifor PharmaBusiness WireAbbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons Regulatory News: Abbas Hussain (56, British citizen) has a s
5y agoGNHAFVifor Pharma to revise DIAMOND study, readout expected in H2 2021Business WireCOVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee recommended new clinically relevant endpoints Data ar
5y agoGNHAF OPKOPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to ViforGlobeNewswireMIAMI, May 24, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announced a transfer of the licensed rights to RAYALDEE® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). On May 17, 2021
5y agoGNHAF93rd Vifor Pharma Group Annual General MeetingBusiness WireShareholders agreed to the Board of Directors' recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved Regulatory News: At today's 93rd Ann
5y agoGNHAFVFMCRP announces positive results of phase-III clinical trial of Velphoro® in ChinaBusiness WireMet primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed Submission to the Chinese Center for Drug Evaluation
5y agoANGN GNHAFVifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associated acute kidney injuryBusiness WireTopline data expected in the second half of 2021 Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210428005922/en/ Vifor Pharma and Angion Biomedica Corp. (NASDAQ:AN
5y agoANGN GNHAFAngion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney InjuryGlobeNewswireUNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion's AKI-002-15 study, a Phase 2 trial of ANG-3777 in patients at risk
5y agoGNHAFFirst patient enrolled in CARE-HK in HF to evaluate role of Veltassa® (patiromer) in enabling RAASi treatmentBusiness WireCARE-HK in heart failure (HF) is the first global registry of around 5,000 patients with chronic HF who have or are at high risk for hyperkalemia (HK), in Europe and the US CARE-HK in HF is designed to evaluate the use of Veltassa® in enabling pa